Calyx (clinical research company)

Calyx, formerly Parexel Informatics,[5] is a corporate spin-off from Parexel International.[2][6] Calyx is a British–American provider of biopharmaceutical services.[7] The company was formed in January 2021 following the strategic separation of the Parexel Informatics business from Parexel International, and provides medical imaging, e-clinical and regulatory services.[8]

CALYX
Company typePrivate
IndustryClinical research organizations
Pharmaceutical
Founded2021
HeadquartersNottingham, United Kingdom[1]
Number of locations
12+ facilities in 10+ countries
Key people
CEO: David Herron
ServicesMedical imaging, clinical trial management systems
Revenue$82 million (2022)[2][3]
Number of employees
1000-2000[4]
Websitecalyx.ai

References
  1. https://www.calyx.ai/locations/
  2. "Merck and Veeva Ink 10-Year Partnership Agreement". BioPharm International.
  3. "Calyx Partnership with Top 5 CRO Extended through 2024". finance.yahoo.com.
  4. "Company".
  5. https://www.clinicalresearchnewsonline.com/news/2022/06/10/calyx-named-medical-imaging-provider-by-clinscience
  6. "Calyx Spins Out of Parexel". Applied Clinical Trials Online.
  7. "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services".
  8. "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services". Retrieved 29 March 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.